Creating medicine is a complex and expensive business. While U.S. biopharmaceutical companies lead the world in drug development, international trade practices can stem the flow of innovation to new markets, depriving patients in need. Limited market penetration also means fewer resources to re-invest in the most successful engine for life-saving advancements on […]
Tag: cures
Drug reference pricing threatens patient health, innovation
By Erik Sass, TES Editor-in-Chief Some recent proposals to lower drug prices are not just counterproductive but dangerous, according to an international panel of expert economists convened by the Competitive Enterprise Institute at the National Press Club on Tuesday, November 5, 2019. The panelists warned that “foreign reference pricing” — a practice […]
Protecting IP is critical to the fight against disease
With the world confronting daunting new health challenges, the UN is emphasizing the need to achieve true universal healthcare. That’s a laudable goal worth supporting — but the same can’t be said for the UN and other global organizations frequent support for measures that jeopardize […]
DELINKAGE: CAN PRIZES REPLACE PATENTS FOR MEDICINE INNOVATION?
By Philip Stevens, Executive Director, Geneva Network Republished with permission of the Geneva Network. Original available here. The patent-based system of drug development comes under further pressure from key countries aiming to increase access to medicines at a joint World Health Organization and Government of India meeting in New Delhi this week. […]